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1 These authors contributed equally to this work.We investigated transactivation by NANOG in regulating growth and differentiation factor 3 (GDF3)
expression in NCCIT cells. GDF3 expression was affected by shRNA-mediated downregulation and by
exogenous overexpression of NANOG speciﬁcally, as well as by retinoic acid-mediated differentia-
tion. GDF3 transcription was activated by NANOG, and the upstream region (183 to 1) was sufﬁ-
cient to induce minimal transcriptional activity. Moreover, NANOG binds to the GDF3 minimal
promoter in vivo and the transcriptional activity is mediated by NANOG transactivation domain.
This study provides the ﬁrst evidence that NANOG is a transcriptional activator of the expression
of the oncogenic growth factor GDF3 in embryonic carcinoma cells.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction factor and a key regulator of embryonic stem cell self-renewalPluripotent stem cells possess the unique capabilities of self-re-
newal, proliferation, and differentiation into multiple cell-types.
Coordinated transcription factor networks including NANOG,
OCT4, and SOX2 have emerged as master regulators of stem cell
pluripotency and differentiation [1]. Germ cell tumors (GCTs),
which arise from primordial germ cells, contain undifferentiated
and pluripotent embryonic carcinoma (EC) cells and exhibit a gene
expression proﬁle similar to that of pluripotent stem cells, includ-
ing expression of the transcription factors NANOG, OCT4, and SOX2
[2]. It has been suggested that deregulation of these networks and
factors may contribute to malignant transformation [3–5].
Especially, NANOG is a novel homeobox-containing transcriptionchemical Societies. Published by E
ctor 3; GCT, germ cell tumor;
iomedical Science, College of
g-Gu, Seongnam-Si, Gyeong-and pluripotency [6,7]. NANOG is expressed not only in GCTs, but
also in other tumors including carcinomas of the breast, cervix, oral
cavity, kidney, and ovary [8–14]. Moreover, ectopic overexpression
of NANOG induced the proliferation and transformation of NIH3T3
and 293T cells; NANOG has also been demonstrated to regulate
human tumor development [15–17].
Growth and differentiation factor 3 (GDF3) belongs to the bone
morphogenic protein/GDF class of the transforming growth factor
b (TGF-b) superfamily [18]. Human GDF3 was ﬁrst identiﬁed in
human carcinoma cells and, subsequently, in primary testicular
germ cell tumors (TGCTs), seminomas, and breast carcinomas
[10,19,20]. In normal tissues, GDF3 is expressed in embryonic stem
cells and the early embryo [21,22]. GDF3-null mice exhibit devel-
opmental abnormalities, suggesting that GDF3 function is required
during embryonic development [19]. Recent work has demon-
strated that GDF3 can induce progression of B16 cell melanomas,
suggesting a possible role in tumor progression [23]. Despite shar-
ing a similar expression pattern in cancers as well as in pluripotent
stem cells, there is no evidence that NANOG and GDF3 interact in
regulating gene expression at the transcriptional level.lsevier B.V. All rights reserved.
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regulates GDF3 gene expression in NCCIT cells, which have a phe-
notype intermediate between seminoma and EC cells and are a
useful tool for studying the relationship between seminoma and
non-seminoma tumorigenesis [24]. This study provides the ﬁrst
evidence that NANOG is a transcriptional activator of the expres-
sion of the oncogenic growth factor GDF3 in EC cells and further
contributes to our understanding of the molecular mechanisms
by which stem cell factors mediate tumorigenesis and pluripotency
processes.2. Materials and methods
2.1. Plasmid construction
The luciferase reporter constructs that contain regions up-
stream of the human GDF3 promoter were generated as follows
and designated as -1721-Luc and -183-Luc. The human GDF3 pro-
moter region (1721 to 1; nucleotide position relative to the
translational start site as +1) was ampliﬁed by PCR using genomic
DNA from NCCIT cells and cloned into the pGL3-basic reporter
plasmid (Promega, Madison, WI, USA). A series of deletion mutants,
in which nucleotides downstream of positions 1339, 1113,
758, 536, 254, and 183 to 1 from the translation start site
of the GDF3 gene were contained, were generated using the full-
length human GDF3 promoter construct as a template. Mutant pro-
moter constructs were produced from the GDF3 minimal promoter
region (183 to 1) using the QuickChange Site-Directed Muta-
genesis method (Stratagene, La Jolla, CA, USA). Human NANOG
and deletion variants were generated using full-length hNANOG
cDNA isolated from NCCIT cells. The constructs were inserted into
the pcDNA3.1 plasmid in frame with a Flag epitope tag. All cloned
PCR products and reporter plasmids were veriﬁed by sequencing.
2.2. Cell culture and differentiation
NCCIT and HEK293T cells (American Type Cell Collection) were
grown in Dulbecco’s Modiﬁed Eagle’s Medium (Life Technologies,
Paisley, UK) supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA). To induce differentiation, NCCIT cells were treated
with 10 lM retinoic acid (RA, Sigma, St. Louis, MO, USA) for
10 days.
2.3. Preparation of short hairpin RNA against hNANOG
Target sequence for hNANOG RNA interference was obtained
from the previous report [25] for maximum silencing efﬁciency.
Two double-stranded oligonucleotides were generated by
annealing 50-GATCCGCCAGACCTGGAACAATTCAGAAGCTTGTGAAT-
TGTTCCAGGTCTGGTTTTTTGGAAGC-30 and 50-GGCCGCTTCCAAAA-
AACCAGACCTGGAACAATTCACAAGCTTCTGAATTGTTCCAGGTCTGG-
CG-30 and inserted into BamHI and NotI-digested pGSH1-GFP
shRNA vector (Genlantis, San Diego, CA, USA). NANOG sense and
antisense sequences are underlined. The hairpin loop structure is
underlined and the HindIII sequence is marked in italics. The
pGSH1-GFP-luciferase shRNA vector used for a control was pro-
vided by the manufacturer.
2.4. Microporation
NCCIT cells were transfected with each shRNA expression vector
or wild-type NANOG expression vector by using a microporator
(1100 volts, 20 ms; Digital Bio Tech., South Korea) and collected
2 days post-transfection for real-time PCR and Western blot
analyses.2.5. RNA preparation and real-time PCR
Total RNAwas prepared fromundifferentiated anddifferentiated
NCCIT cells and subjected to reverse transcription using 5 lg total
RNA, oligo dT primers (Promega), and Moloney murine leukemia
virus reverse transcriptase (Invitrogen, Grand Island, NY, USA). The
cDNAs were ampliﬁed with real-time PCR mix containing the DNA
binding dye SYBR green (Bioneer, Daejeon, South Korea). The for-
ward and reverse primers for quantitative real-time RT-PCR were
as follows: GDF3 (150 bp), 50- AGACTTATGCTACGTAAAGGAGCT -30
and 50- CTTTGATGGCAGACAGGTTAAAGTA -30; NANOG (107 bp),
50- CCCAAAGGCAAACAACCCACTTCT -30 and 50- AGCTGGGTGGAA-
GAGAACACAGTT -30; and GAPDH (226 bp), 50- GAAGGTGAAGGTCG-
GAGTC -30 and 50- GAAGATGGTGATGGGATTTC -30. GAPDH cDNA
was ampliﬁed from all samples as a normalizing control. Relative
quantiﬁcation of the expression levels was determined using the
2-DDCT method [26].
2.6. Western blot analysis
NCCIT cells transfected with NANOG shRNA or Flag-tagged NA-
NOG expression vector were harvested 48 h after transfection. For
Western blot analysis, cells were lysed with 1 ml of RIPA buffer
containing 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 50 mM Tris (pH 8.0), and 50 lM MG-132 protea-
some inhibitor (EMD Millipore, Billerica, MA, USA) on ice for
20 min. Whole cell lysates were separated by 10% SDS–polyacryl-
amide gel electrophoresis and proteins were transferred to a PVDF
membrane (GE Healthcare, Waukesha, WI, USA). Membranes were
blocked in 5% non-fat milk and then incubated with an anti-Flag
monoclonal (1:2500, Sigma), anti-NANOG polyclonal (1:2500, San-
ta Cruz Biotechnology, Santa Cruz, CA, USA), anti-GDF3 polyclonal
(1:1000, Abcam, Cambridge, MA, USA), and anti-b-actin monoclo-
nal (1:2500, Santa Cruz Biotechnology) antibodies, followed by
incubation with a horseradish peroxidase-conjugated secondary
antibodes (1:5000, Santa Cruz Biotechnology). Immunoreactive
proteins were visualized using an enhanced chemiluminescence
detection kit (Thermo Scientiﬁc, Rockford, IL, USA).
2.7. Transient transfection and reporter assays
NCCIT and HEK 293T cells were used for transient transfection
and reporter assays were performed in duplicate in three or more
independent experiments, as described in previous reports [27,28].
2.8. Chromatin immunoprecipitation
Naïve NCCIT cells were ﬁxed in 1% formaldehyde for 10 min at
room temperature, resuspended in 1 ml of swelling buffer
(100 mM Tris, pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP40,
1 mM DTT and protease inhibitors) and incubated for 30 min on
ice. After centrifugation at 4 C for 10 min, nuclei were resuspended
in 1.5 ml of sonication buffer (50 mM Tris, pH 8.0, 140 mM NaCl,
1 mM EDTA, 1% TritonX-100, 0.1% SDC, 0.1% SDS and protease
inhibitors) and sonicated 8 times for 20 s, resulting in an average
fragment size of 1000 bps. Chromatin was precleared with salmon
spermDNA and protein G-plus agarose beads (Santa Cruz) for 4 h at
4 C. Precleared chromatin (1 ml)was rotated overnight at 4 Cwith
3 ll of the rabbit monoclonal anti-NANOG antibody (Cell Signaling)
or normal rabbit IgG (Cell Signaling). Chromatin/antibody com-
plexes were incubated with 50 ll of Protein G-plus agarose beads
for 6 h. Agarose beads were washed with immune complex wash
buffers in the following order: low salt (20 mM Tris, pH 8.0,
150 mM NaCl, 2 mM EDTA, 1% TritonX-100, 0.1% SDS), high salt
(20 mM Tris, (pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% TritonX-100,
0.1% SDS), LiCl (10 mM Tris, pH 8.0, 0.25 M LiCl, 1 mM EDTA, 1%
Fig. 1. Expression analyses of GDF3 and NANOG in NCCIT cells during retinoic acid-mediated differentiation for 10 days and effect of NANOG downregulation and
upregulation on GDF3 expression. (A) Morphological changes were observed by microscopic examination. (B) Real-time PCR analysis of GDF3 and NANOG in undifferentiated
and differentiated NCCIT cells. ⁄⁄P < 0.01. (C) and (D) shRNA-mediated downregulation and exogenous overexpression of NANOG in NCCIT cells. Abundance of NANOG and
GDF3 mRNA transcripts was measured by real-time PCR, which is relative to those of control transfectants. GAPDH was used as an internal control for normalization of cDNA
content. Data represent the means and S.D. from three independent experiments that were performed in duplicate. abcP < 0.05 (C). Western blot analysis of GDF3 and NANOG
protein expression in NCCIT cells using anti-NANOG, anti-Flag and anti-GDF3 antibodies. b-Actin was used as an internal control for normalization of total protein content (D).
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precipitated DNA was then used as the template for quantitative
PCR using primers speciﬁc for the hGDF3 promoter using the Green-
star qPCR premix (Accupower, Bioneer). Primer sequences were as
follows: GDF3p (144 to47) 50-CTCTTCACATCCAATGGCCT-30 and
50-TGCCCAACAATTCAGAGGCT-30; GDF3p (+685 to +819) 50-
CTTCATGCTTCCCTGCTGGT-30 and 50- GAATAGCTGGTGACGGTGGC-
30; and GDF3p (624 to 422) 50-GTCTAATCCAGGGGTGTCCA-30
and 50-GTCACATGAGGCTCACGATG-30.
2.9. Statistical analysis
The data were analyzed by t-Test and Duncan’s multiple range
procedure for multiple comparisons using SigmaPlot 11.0 program
(Systat Software, Inc., San Jose, CA, USA). In all experiments,
P < 0.05 was considered statistically signiﬁcant.
3. Results and discussion
3.1. Expression of GDF3 and the stem cell transcription factor NANOG
in NCCIT cells
Many stem cell-associated genes are also expressed in GCTs,
providing evidence of a link between stem cells and cancer
[10]. Human NANOG and GDF3 are expressed in pluripotent cells
and the genes are co-localized at chromosome 12p, a regionconsistently overrepresented in human GCTs as a hot spot for
teratocarcinomas [21]. It has been reported that RA treatment sup-
presses the tumorigenecity of embryonic carcinoma cells, suggest-
ing that these genes have a crucial role in TGCT and indicating a
link between pluripotency and transformation [29]. Based on these
reports, we analyzed the expression pattern of GDF3 and NANOG
in undifferentiated and differentiated NCCIT cells (differentiation
mediated by treatment with 10 lM RA for 10 days). After 10 days,
dramatic morphological changes were observed by microscopic
examination (Fig. 1A). GDF3 and NANOG transcripts were readily
detectable in undifferentiated NCCIT cells and were signiﬁcantly
downregulated upon RA-mediated differentiation (Fig. 1B). To fur-
ther ﬁnd a direct relationship at the transcription level, shRNA-
mediated knockdown and exogenous overexpression of NANOG
were induced in NCCIT cells and relative expression was analyzed
by real-time PCR (Fig 1C). Expression of endogenous GDF3 as well
as NANOG was signiﬁcantly reduced by shRNA-mediated NANOG
RNA interference. In addition, overexpression of exogenous NA-
NOG led to an increase in the endogenous GDF3 expression. We
further conﬁrmed that shRNA-mediated RNA interference and
overexpression of NANOG could also affect GDF3 protein expres-
sion by Western blot analysis using antibodies speciﬁc to NANOG
and GDF3. Exogenous NANOG expression was also conﬁrmed by
using anti-Flag antibody (Fig 1D). These data strongly support
our hypothesis that NANOG is implicated in GDF3 gene expression
in NCCIT cells.
Fig. 2. The GDF3 promoter is activated by NANOG in a dose-dependent manner. Transcriptional activity was calculated relative to the expression of pGL3-basic as a negative
control. Data represent the means and standard deviation (S.D.) from three independent experiments that were performed in duplicate. Values with different letters are
signiﬁcantly different. abcP < 0.05. abcdP < 0.05.
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manner
Despite sharing a similar expression pattern in cancer as well as
stem cells, there is no information available on the molecular
mechanisms of the regulation of NANOG and GDF3. To investigate
the functional relationship between these factors at the transcrip-
tional level, a GDF3 promoter reporter (-1721-Luc) was co-trans-
fected with increasing amounts of a NANOG expression vector.
Transcriptional activity of the GDF3 reporter was increased in a
dose-dependent manner in pluripotent NCCIT and non-pluripotent
HEK293T cells (Fig. 2). The activity was signiﬁcantly greater in HEK
293T cells than in NCCIT, potentially due to the presence or
absence of different endogenous factors depending on different
cell-types.Fig. 3. The GDF3 promoter is tightly regulated in pluripotent NCCIT cells. The diagram
calculated relative to the expression of pGL3-basic as a negative control. Data represen
duplicate. Values with different letters are signiﬁcantly different. abcdP < 0.05.3.3. The GDF3 promoter is tightly regulated in pluripotent NCCIT cells
To determine the functional signiﬁcance of the transcriptional
activation of the GDF3 promoter by NANOG, a series of deletion
constructs possessing parts of the 50-upstream region, starting at
1339,1113, 758, 536, 254, or 183 bp from the translation
start site, were constructed. The deletion constructs were transfec-
ted into NCCIT cells expressing endogenous GDF3 and NANOG
(Fig. 3). Luciferase activity of the full-length GDF3 promoter
(-1721-Luc) increased 2-fold relative to the promoterless pGL3
control vector. The deletion mutants (-1339-Luc, -1113-Luc, or -
758-Luc) slightly increased the promoter activity, compared to
the full-length GDF3 promoter. The 50-upstream deletion mutant
(-536-Luc) decreased the reporter activity, but further deletion
mutants (-254-Luc and -183-Luc) recovered the promoter activity.represents the GDF3 promoter serial deletion mutants. Transcriptional activity was
t the means and S.D. from four independent experiments that were performed in
Fig. 4. Identiﬁcation of putative NANOG-binding sites within the GDF3 minimal promoter. (A) Upper panel: Sequence alignment of mouse and human GDF3 upstream of the
translation initiation sites. Sequence identities are indicated (⁄) and the two putative NANOG-binding sites in bold and underlined. Lower panel: Schematic diagram of the
locations and sequences of the wild-type (WT) and mutated (Mut) putative binding motifs. (B) Transient transfection and luciferase activity of GDF3 WT minimal promoter
and site-directed mutants were co-transfected with a control or a NANOG expression vector in NCCIT and HEK293T cells. Transcriptional activity was calculated relative to
the expression of pGL3-basic as a negative control. The transcriptional activity of the GDF3 WT or Mut promoter alone (white bars) was compared to the transcriptional
activity of GDF3 WT or Mut promoter induced by NANOG overexpression (black bars). Data represent the means and S.D. from four independent experiments that were
performed in duplicate. ⁄⁄P < 0.01, ⁄P < 0.05.
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elements may be present between 758 to 536 bp and 254 to
183 bp, respectively. In addition, the transcriptional activity of
the smallest GDF3 promoter fragment (-183-Luc) recovered the
activity equivalent to the full-length promoter. These results indi-
cate that the GDF3 promoter is tightly regulated and that the re-
gion (183 to 1) is sufﬁcient for basal activation of GDF3
promoter activity.
3.4. Putative NANOG-binding sites are present within the GDF3
minimal promoter region
To determine the evolutionarily conserved binding sites within
the GDF3 minimal promoter that may play a critical role in the reg-
ulation of GDF3 gene expression, a sequence analysis of the region
upstream in both the human and mouse GDF3 gene was conducted
using the TFSEARCH database (http://mbs.cbrc.jp/research/db/TFSEARCH.html). Two putative NANOG-binding sites in the human
sequence were identiﬁed. One sequence, nucleotide position 61
to 50 (50-CTCTGAATTGTTGGGCAG-30, 1st binding site), was not
entirely conserved between human and mouse (bold and under-
lined) and the other, at 97 to 84 (50-CACTTGATTATCTT-30, 2nd
binding site), was completely conserved between human and
mouse (Fig. 4A).
To examine whether the two putative binding sites are func-
tionally active and NANOG is capable of inducing transcriptional
activation of the GDF3 minimal promoter through them, the
GDF3 wild-type minimal promoter, or mutants (mutated in 1st,
2nd, or 1st and 2nd binding sites), were co-transfected with the
NANOG (black box) expression vector or with an empty expression
vector (control, white box) into NCCIT and HEK293T cells (Fig. 4B).
In both cell lines, the GDF3 promoter alone is activated to some ex-
tent but is more signiﬁcantly activated by NANOG overexpression.
Mutations at the 2nd binding site, which is completely conserved
Fig. 5. Binding of NANOG to the GDF3 minimal promoter via ChIP analysis. (A)
Schematic diagram of the locations of the GDF3 primers corresponding to positions
624 to 422 (a), 144 to 47 (b), and +685 to +819 (c). (B) The putative NANOG-
binding sites were analyzed by real-time PCR. Data represent the means and S.D.
from ﬁve independent experiments that were performed in duplicate. The
enrichment of the GDF3 promoter target region (144 to 47) was visualized by
gel electrophoresis. Input DNA, anti-rabbit IgG-precipitate, and no antibody
samples were ampliﬁed by real-time PCR as positive and negative controls. Values
with different letters are signiﬁcantly different. abP < 0.05.
Fig. 6. Transcriptional activity of the GDF3 promoter is mediated by the NANOG C-
terminal transactivation domain. (A) Schematic representation of NANOG full-
length and deletion mutant derivatives tagged with the Flag epitope. (B) The
minimal GDF3 promoters (-183-Luc) were used for reporter assay. Transcriptional
activity of the indicated constructs in HEK293T cells was calculated relative to the
expression of pGL3-basic control vector. Data represent the means and S.D. from
three independent experiments that were performed in duplicate. Values with
different letters are signiﬁcantly different. abP < 0.05.
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regulation of the transcriptional activity than mutations at the
1st binding site. However, mutations at both the 1st and 2nd bind-
ing site signiﬁcantly decreased the GDF3 promoter activity even in
cells overexpressing NANOG. Taken together, these results suggest
that the two putative binding sites are functionally important for
NANOG regulation of GDF3 gene expression.
3.5. NANOG binds to the GDF3 minimal promoter in vivo
Whether NANOG could bind to the region containing the two
putative binding elements in native chromatin of undifferentiated
NCCIT cells was examined using a ChIP assay (Fig. 5). Chromatin
was prepared from undifferentiated NCCIT cells expressing NANOG
and GDF3, and NANOG-bound chromatin was enriched with an
anti-NANOG antibody. The putative NANOG-binding sites were
analyzed by real-time PCR using the GDF3 promoter-speciﬁc prim-
ers. Three pairs of primers were used to amplify the region (144
to 47 depicted as b) spanning the two putative binding sites, and
two other sites (624 to 422 depicted as a and +685 to +819 as c)
were used as upstream and downstream negative controls. The re-
gion b (144 to 47) chromatin, which contains the putative NA-
NOG-binding sites, was signiﬁcantly enriched compared to regions
a and c. These results indicate that NANOG can bind to speciﬁc
sites within the GDF3 minimal promoter and also suggest that
the GDF3 minimal promoter may be sufﬁcient for inducing tran-
scriptional activity mediated by NANOG via direct interactionswith the two putative binding sites. A GDF3-NANOG interaction
has been detected by ChIP-ChIP assays in human embryonic stem
cells [1] and has also suggested that GDF3 is likely to be a target
directly activated by NANOG in both undifferentiated human
embryonic stem and embryonic carcinoma cells [30].
3.6. Transcriptional activity of the GDF3 promoter is mediated by the
NANOG C-terminal transactivation domain
To conﬁrm whether the transcriptional activation of the GDF3
promoter is mediated by the transactivation domains of NANOG,
constructs containing the transactivation domains and spanning
the DNA binding domain were generated based on previous report
[31]. The constructs were the N-terminal domain (ND) to homeo-
domain (HD), the HD, and the HD to C-terminal domain (CD) of hu-
man NANOG (Fig. 6A). Expression vectors containing each
construct were co-transfected into HEK293T cells together with
GDF3 reporter vector (-183-Luc) (Fig. 6B). Compared with tran-
scriptional activation mediated by the NANOG full-length and
the CD, deletion mutants containing only the ND to HD or HD alone
led to a signiﬁcant reduction in transcriptional activity of the GDF3
promoter. These results support our previous ﬁndings that the hu-
man NANOG CD acts as a transactivation domain [31,32] and fur-
ther indicate that the NANOG CD mediates transcriptional
activation of the GDF3 promoter.
Understanding the underlying molecular mechanisms regulat-
ing stem cell transcription factors and their downstream effector
gene(s) is crucial for identifying key genes or proteins that can
be exploited as diagnostic biomarkers in tumorigenesis, as well
as stem cell-speciﬁc molecular markers in pluripotency. Pluripo-
tency is regulated by coordinated transcription factor networks
S.-W. Park et al. / FEBS Letters 586 (2012) 3529–3535 3535and multiple signaling molecules. The aberrant functioning of
these complex and coordinated stem cell regulators may contrib-
ute to malignant transformation and tumorigenesis [3]. In sum-
mary, our ﬁndings demonstrate that NANOG functions to activate
GDF3 transcription by directly binding to two motifs in the mini-
mal promoter sequence in pluripotent NCCIT cells, suggesting a
crucial role in both germ cell tumorigenesis and pluripotency.
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